secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001193125-24-200247
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q2 2024: YCANTH revenue $4.9M; net loss $17.2M; positive Phase 2 BCC data
--------------------------------------------------------------------------------

- Net product revenue of $4.9M from YCANTH; net loss $17.2M ($0.37/sh) vs $11.0M ($0.24/sh) in Q2 2023.
- Cash and equivalents $31.9M; expects runway into Q1 2025.
- Phase 2 VP-315: 51% complete histologic clearance of basal cell carcinoma; no serious adverse events.
- Permanent J-Code for YCANTH effective Apr 1; settlement with Dormer Labs to stop unapproved cantharidin sales in US.
- Amended Torii agreement: equal cost split for Phase 3 common warts trial; $8M milestone at first Japan patient dosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524200247/0001193125-24-200247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524200247/d857642d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-200247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer